RESS MAIL NO. EV484957987US U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1390 (REV. 10-2003) ATTORNEY DOCKET NUMBER 47675-93 TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP2003/010881 October 1, 2003 (10/01/03) October 1, 2002 (10/01/02) TITLE OF INVENTION METHOD AND NUCLEIC ACIDS FOR THE IMPROVED TREATMENT OF BREAST CELL PROLIFERATIVE **DISORDERS** APPLICANT(S) FOR DO/EO/US FOEKENS, John, HARBECK, Nadia, KOENIG, Thomas, MAIER, Sabine, MARTENS, John, MODEL, Fabian, NIMMRICH, Inko, RUJAN, Tamas, SCHMITT, Armin, SCHMITT, Manfred, LOOK, Maxime, P., MARX, Almuth, HOEFLER, Heinz Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. In the US has been elected (Article 31). 5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). b. X has been communicated by the International Bureau. c. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. is attached hereto. b. has been previously submitted under 35 U.S.C. 154(d)(4). 7. X Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. are attached hereto (required only if not communicated by the International Bureau). b. X have been communicated by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. d. | have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern document(s) or information included: 11. An information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. X A preliminary amendment. 14. X An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A power of attorney and/or change of address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825.

SEA 1578061v1 47675-93

20. X Other items or information: Sequence Statement

18. A second copy of the published international application under 35 U.S.C. 154(d)(4).

19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).

U.S. APPLICATION NO. (if known, see 37 CFR 1.15) INTERNATIONAL APPLICATION NO				ATTORNEY'S DOCKET NUMBER		
Not yet known 0 / 517741 PCT/EP2003/010881				47675-93		
21. ☐ The following fees are submitted:					LCULATIONS	PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):						- · · · · · · · · · · · · · · · · · · ·
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1080.00						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$ 1000.00						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 770.00						
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 730.00						
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00						
ENTER APPROPRIATE BASIC FEE AMOUNT =					00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).						
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$		
Total claims	20 =	59	x \$ 25.00		1475,00	
Independent claims	3 =	8	x \$ 100.00	\$	800,00	
MULTIPLE DEPENDEN	NT CLAIM(S) (if applic	1	+ \$369.00 180.	\$	180,00	
Additional sheet fee (each add'l. 50 sheets exceeding 100 + \$250.00					250.00	
TOTAL OF ABOVE CALCULATIONS =					WEST 3705	, <i>o</i> v
Applicant claims small entity status. See 37 CFR 1.27. the fees indicated above are reduced by ½.					5	
SUBTOTAL =					,705.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					a	
TOTAL NATIONAL FEE =					,70S.OU	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						
TOTAL FEES ENCLOSED =					705.00	
				A	mount to be refunded:	\$
					charged:	\$
a. A check in the amount of \$ to cover the above fees is enclosed.						
b. A duplicate copy of this sheet is enclosed. By Please charge my Deposit Account No. 04-0258 in the amount of \$13,705,00 to cover the above fees.						
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-0258. A duplicate copy of this sheet is enclosed.						
d. [] Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.						
// \w. \ / \h/\						
SEND ALL CORRESPONDENCE TO: Davis Wright Tremaine LLP					~/UW~	
Davis Wright Tremaine LLP 2600 Century Square						
1501 Fourth Avenue Barry L. Da					<u>n, Ph.D</u> ., J.D.	
Seattle, WA 98101-1688 NAME						
Phone: (206) 628-7508 Fax: (206) 628-7699 47,309						
REGISTRAT					NUMBER	

CERTIFICATE OF MAILING VIA U.S. EXPRESS MAIL

Applicants:

Foekens et al.

Title:

METHOD AND NUCLEIC ACIDS FOR THE IMPROVED

TREATMENT OF BREAST CELL PROLIFERATIVE DISORDERS

U.S. Application No.: to be assigned

International

Application No.:

PCT/EP2003/010881

Attorney Docket No.: 47675-93

Date of Deposit:

December 11, 2004

EXPRESS MAIL LABEL NUMBER: EV484957987US

I hereby certify that this paper, along with an accompanying Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning A Filing Under 35 U.S.C. 371 (2 pages), Application Data Sheet, Preliminary Amendment and Sequence Listing, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date listed below, addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

December 11, 2004

Barry L. Davison, Ph.D., J.D.

Printed Name